General | Apogee Therapeutics, Inc.

Skip to main navigation

About us Our science Our programs Patients Investors Careers

About us Our science Our programs Patients Investors Careers

Corporate Presentation

Stock Information

Stock Quote & Chart

Corporate Governance

Documents & Charters

Board of Directors

Committee Composition

Financial Information

Quarterly Results

code

General

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Read more about Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Read more about Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

Read more about Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

Read more about Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

Read more about Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

Read more about Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

Apogee Therapeutics to Participate in Upcoming March Conferences

Read more about Apogee Therapeutics to Participate in Upcoming March Conferences

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026

Read more about Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

Read more about Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

Read more about Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

Pagination

Page 1
Next page

Subscribe to General

to stay updated

Our science Background & Goal Approach Therapeutic Targets Publications

Our programs Pipeline Programs

About us Story & Mission People Contact

Careers Values Benefits Careers

Patients Apogee Commitment Science Simplified Clinical Trials & Disease Ed

Investors Corporate Presentation Overview News & Events Stock Information Corporate Governance Financial Information IR Resources

Terms of Service Privacy Policy Cookies Policy

© 2026 Apogee Therapeutics, Inc. All rights reserved.

Design by Visual Science 2024